Amplitude Surgical: directors' dealings · France · AMF

About Amplitude Surgical

Amplitude Surgical is a French medical technology company focused on the design, manufacture, and marketing of implants and surgical solutions for lower-limb orthopaedics. Founded in 1997 in Valence, France, the company has built a strong reputation in hip, knee, and extremity procedures, with particular expertise in foot and ankle surgery. From its origins as a French specialist, Amplitude Surgical expanded through a network of subsidiaries, exclusive distributors, and agents, while maintaining a solid industrial and commercial footprint in France. The company is listed on Euronext Paris under ticker AMPLI and ISIN FR0012789667. Amplitude Surgical’s core business is centered on a broad portfolio of products for primary and revision surgery, including orthopedic implants, associated instrumentation, and value-added services. Its offering covers major lower-limb pathologies, especially hip and knee replacement, and is complemented by technologies designed to improve surgical precision and workflow. These include computer-assisted surgery systems, custom-made single-use instrumentation solutions, and platforms aimed at supporting less invasive and more accurate procedures. This integrated model, developed in close collaboration with orthopedic surgeons, is one of the company’s key competitive differentiators in a highly regulated and competitive market. From a market standpoint, Amplitude Surgical has historically combined steady growth with profitability, with most revenue generated in France and an increasing international contribution over time. The group states that its products are used in more than 400 healthcare facilities in France and have been sold in more than 30 countries. Recent financial disclosures show annual revenue of €110.8 million for fiscal year 2024-25, following €106.0 million in fiscal 2023-24, while the group employed 428 people as of June 30, 2024. These figures reinforce Amplitude Surgical’s position as a leading French specialist in lower-limb orthopaedic surgical technologies, with a solid domestic base and meaningful room for international expansion. A notable recent development was the 2025 acquisition process involving Zydus Lifesciences, which agreed to acquire a majority stake from PAI Partners and other shareholders, followed by a simplified tender offer. This transaction highlights the strategic value of the company within the European medtech landscape and underlines its relevance as an orthopaedic platform with growth potential.